cell-therapy-public-health-congress-2019-keynote

9 / 14

Note:
Page 20
April 15-16, 2019 | Milan, Italy
&
PUBLIC HEALTH,
EPIDEMIOLOGY AND NUTRITION
2nd World Congress on
CELL AND GENE THERAPY
2nd International Conference on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
Joint Event on
Cell and Gene Therapy 2019 & Public Health Congress 2019 Archives of General Internal Medicine | ISSN: 2591-7951 | Volume 3
SUCCESSFULLY ACTIVATING POSITIVE
BEHAVIORS OF THE STAKEHOLDERS
INVOLVED IN VACCINE PURCHASING
AND USAGE THROUGH
TECHNOLOGICAL ADVANCES
The vaccine segment is anticipated to be one of the fastest growing,
one of the healthcare industry and several leading firms have stepped
up vaccine investments in recent years. Unlike therapeutic agents, vac-
cines are administered to healthy individuals only once or very infre-
quently during a life time. Vaccines generate well-documented positive
externalities, yet their poor awareness and acceptability among vaccine
end-users may contribute to resurgence of transmissible diseases and
consequently trigger governmental interventions such as mandating
vaccination. In addition to technical and clinical development per the
highest quality standards, bringing new vaccines tomarket requires care-
fully orchestrated programs targeting the multiple types of stakeholders
along the entire value chain and addressing their respective purchasing
behavioral drivers. Against a backdrop of anti-vaccination buzz and vac-
cine fatigue, successful global launch and sustainable usage of a vaccine
requires the development of a multi-pronged strategy addressing all as-
pects in relation to acceptability (e.g. themotivation to immunize despite
the quasi-disappearance of the disease), accessibility (e.g. supply chain
services), availability (e.g. mechanisms ensuring reliability of supply) and
affordability (e.g. tiered pricing policy taking country differences in per
capita income into account). Leveraging novel technological advances
can positively influence the ability to activate these levers successfully.
Pierre A Morgon, Arch Gen Intern Med 2019, Volume 3
DOI: 10.4066/2591-7951-C2-025
Pierre A Morgon is Chief Executive Officer of
MRGN Advisors, a consultancy advising CEOs
and investors in the healthcare sector and re-
gional partner for Switzerland at Merieux devel-
opment and an evergreen investment fund. He is
a lecturer in several MBA programs in world-class
business schools and in life science conferences
and at the mass challenge incubator in Swit-
zerland where he mentors start-up life scienc-
es companies. He is also holding the following
board positions: Chairman of the board of Vi-
rometix; Non-Executive; Director to the Board of
Theradiag; Non-Executive Director to the Board
of Eurocine Vaccines; Non-Executive Director to
the Board of Vaccitech; Non-Executive Director to
the Board of Univercells. He holds a Doctorate of
Pharmacy, Master’s in Business Law and an MBA
Degree.
Pierre A Morgon
MRGN Advisors, Switzerland
BIOGRAPHY